Pharmacodynamics of Antimicrobials

  1. Ambrose PG, Bhavnani SM, Rubino CM, et al.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy:  it’s not just for mice anymore.  Clin Infect Dis 2007;44:79-86.
  2. Andes D.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.  Antimicrob Agents Chemother 2003;47:1179-86.
  3. Andes D, vanOgtrop ML, Peng J, et al.  In vivo pharmacodynamics of a new oxazolidinone (linezolid).  Antimicrob Agents Chemother 2002;46:3484-9.
  4. Craig WA.  Does the dose matter?  Clin Infect Dis 2001;33(suppl 3):S233-7.
  5. Craig WA.  Pharmacokinetic/pharmacodynamic parameters:  rationale for antibacterial dosing of mice and men.  Clin Infect Dis 1998;26:1-12.
  6. Crandon JL, Nicolau DP.  Pharmacodynamic approaches to optimizing beta-lactam therapy.  Crit Care Clin 2011;27:77-93.
  7. Falagas ME, Vouloumanou EK, Samonis G, et al.  Fosfomycin.  Clin Microbiol Rev 2016;29:321-47  doi:10.1128/CMR.00068-15.
  8. Gilbert DN, Moellering RC, Eliopoulos GM, eds.  The Sanford guide to antimicrobial therapy 2012. Sperryville, VA:  Antimicrobial Therapy, Inc. 2012.
  9. Michalopoulos AS, Falagas ME.  Colistin:  recent data on pharmacodynamics properties and clinical efficacy in critically ill patients.  Ann Intensive Care 2011;1:30-5.
  10. Reffert JL, Smith WJ.  Fosfomycin for the treatment of resistant gram-negative bacterial infections.  Pharmacotherapy 2014;34:845-57  doi:10.1002/phar.1434.
  11. Roberts JA, Lipman F.  Pharmacokinetic issues for antibiotics in the critically ill patient.  Crit Care Med 2009;37:840-51.
  12. Wilby KJ, Nasr ZG, Elazzazy S, et al.  A review of clinical outcomes associated with two meropenem dosing strategies.  Drugs R D 2017;17:73-8.
  13. Wispelway B.  Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.  Clin Infect Dis 2005;40(suppl 7):S439-47.